Clinical Trial Update: Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

View source ↗

Summary

This update reports the completed post-marketing surveillance study of Jardiance (empagliflozin) in Korean patients with chronic heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Jardiance (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Heart Failure | Status: COMPLETED